Results 11 to 20 of about 14,494 (232)

Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. [PDF]

Neurol Neuroimmunol Neuroinflamm
Objectives Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal CNS infection caused by reactivation of JC virus, typically in immunocompromised patients. No effective antiviral therapy has been established.
Torkildsen Ø, Bru ANS, Behzadi GIN, Myhr KM.   +3 more
europepmc   +2 more sources

Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe. [PDF]

HIV Med
To compare BMI‐for‐age z‐score (zBMI) changes in treatment‐experienced children and young people living with HIV aged 6 to
European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group.
europepmc   +2 more sources

Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques. [PDF]

J Infect Dis, 2023
Vaginal inserts that can be used on demand before or after sex may be a desirable HIV prevention option for women. We recently showed that inserts containing tenofovir alafenamide fumarate (TAF/20mg) and elvitegravir (EVG/16mg) were highly protective ...
Makarova N, Singletary T, Peet MM, Mitchell J, Bachman S, Holder A, Dinh C, Lipscomb J, Agrahari V, Mendoza M, Pan Y, Heneine W, Clark MR, García-Lerma JG, Doncel GF, Smith JM.   +15 more
europepmc   +2 more sources

Deep sequencing analysis of hepatitis B virus in patients with incomplete response to tenofovir alafenamide fumarate treatment. [PDF]

World J Hepatol
BACKGROUND Tenofovir alafenamide fumarate (TAF) is one of the first-line treatments used to treat chronic hepatitis B patients; TAF has strong antiviral activity and a high barrier to resistance.
Yamada N, Igarashi H, Murayama A, Suzuki M, Yasuda K, Saito M, Isogawa M, Kato T.   +7 more
europepmc   +2 more sources

Efficacy and Safety of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Treating Acute-on-Chronic Liver Failure with Hepatitis B Virus: A Network Meta-analysis. [PDF]

Infect Dis Ther
Oral nucleos(t)ide analogues (NAs) are widely used in managing hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Among first-line therapies, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are ...
Liu J, Bi Y, Ma X, Xin Y.
europepmc   +2 more sources

Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. [PDF]

BMC Gastroenterol, 2023
Background Nucleoside analogues are currently applied as a first-line treatment for chronic hepatitis B (CHB) patients. However, the long-term effects of this type of treatment on kidney and bone tissue need to be further investigated.
Liu Z, Zhao Z, Ma X, Liu S, Xin Y.
europepmc   +2 more sources

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan. [PDF]

Viruses
Background: Antiretroviral therapy has transformed HIV infection from a fatal disease to a chronic and manageable condition, but increasing health issues beyond acquired immunodeficiency syndrome, such as metabolic, liver, and cardiovascular diseases ...
Trizzino M, Gaudiano R, Arena DM, Pipitò L, Gioè C, Cascio A.   +5 more
europepmc   +2 more sources

Comparison of efficacy and safety of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate treatment in patients with high viral load of hepatitis B virus. [PDF]

Medicine (Baltimore)
Nucleos(t)ide analogues (NAs) have demonstrated potent efficacy in suppressing viral replication in chronic hepatitis B (CHB). This 48-week study compared the efficacy and safety of NA treatment for CHB patients with high viral load (hepatitis B virus ...
Zhang C, Chen X, Hong Z, Qi Y, Wang X, Dai Y, Qiu Y.   +6 more
europepmc   +2 more sources

Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV. [PDF]

AIDS, 2023
Objective: Bone loss in people with HIV (PWH) is poorly understood. Switching tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has yielded bone mineral density (BMD) increases.
Moore AEB, Burns JE, Sally D, Milinkovic A, Krokos G, John J, Rookyard C, Borca A, Pool ERM, Tostevin A, Harman A, Dulnoan DS, Gilson R, Arenas-Pinto A, Cook GJR, Saunders J, Saunders J, Dunn D, Blake GM, Pett SL.   +19 more
europepmc   +2 more sources

Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins.

JAMA Netw Open, 2023
This cohort study examines the risk of incident hypertension and statin initiation among adults starting pre-exposure prophylaxis with tenofovir alafenamide fumarate compared with propensity score–matched adults taking tenofovir disoproxil fumarate.
Rivera AS, Pak KJ, Mefford MT, Hechter RC.   +3 more
europepmc   +2 more sources